Jerry D Cavallerano, O.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Retinopathy | 66 | 2024 | 1268 | 4.940 |
Why?
|
| Ophthalmology | 10 | 2023 | 549 | 1.290 |
Why?
|
| Photography | 18 | 2024 | 530 | 1.280 |
Why?
|
| Telemedicine | 21 | 2024 | 3018 | 1.050 |
Why?
|
| Diabetes Mellitus | 12 | 2024 | 5890 | 0.730 |
Why?
|
| Retinal Vessels | 9 | 2020 | 836 | 0.690 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 10 | 2016 | 250 | 0.590 |
Why?
|
| Macular Edema | 8 | 2023 | 374 | 0.580 |
Why?
|
| Retina | 13 | 2024 | 2635 | 0.550 |
Why?
|
| Telepathology | 7 | 2016 | 77 | 0.470 |
Why?
|
| Vitrectomy | 3 | 2014 | 391 | 0.440 |
Why?
|
| Vision Screening | 2 | 2005 | 69 | 0.440 |
Why?
|
| Fluorescein Angiography | 8 | 2020 | 1045 | 0.420 |
Why?
|
| Mydriatics | 7 | 2022 | 67 | 0.420 |
Why?
|
| Vision Tests | 3 | 2010 | 158 | 0.360 |
Why?
|
| Pupil | 6 | 2016 | 141 | 0.350 |
Why?
|
| Diagnostic Imaging | 6 | 2016 | 3527 | 0.300 |
Why?
|
| Visual Acuity | 6 | 2015 | 2643 | 0.250 |
Why?
|
| Vitreous Body | 2 | 2024 | 399 | 0.240 |
Why?
|
| Vision, Low | 1 | 2006 | 163 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 1 | 13 | 2016 | 3454 | 0.220 |
Why?
|
| United States Indian Health Service | 1 | 2023 | 31 | 0.210 |
Why?
|
| Growth Inhibitors | 1 | 2004 | 378 | 0.210 |
Why?
|
| Cataract Extraction | 1 | 2007 | 465 | 0.210 |
Why?
|
| Retinal Hemorrhage | 3 | 2017 | 95 | 0.200 |
Why?
|
| Retinal Diseases | 4 | 2017 | 702 | 0.200 |
Why?
|
| Physical Examination | 3 | 2013 | 1244 | 0.190 |
Why?
|
| Ophthalmoscopy | 3 | 2017 | 171 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 15 | 2022 | 12289 | 0.180 |
Why?
|
| Endocrinology | 2 | 2020 | 443 | 0.170 |
Why?
|
| Protein Kinase C | 1 | 2004 | 1199 | 0.160 |
Why?
|
| Hemangioblastoma | 2 | 2013 | 63 | 0.160 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2013 | 151 | 0.150 |
Why?
|
| Visual Perception | 1 | 2006 | 1374 | 0.140 |
Why?
|
| Retinal Neovascularization | 3 | 2015 | 273 | 0.140 |
Why?
|
| Eye | 3 | 2024 | 710 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2012 | 8950 | 0.130 |
Why?
|
| Tomography, Optical Coherence | 5 | 2023 | 2884 | 0.130 |
Why?
|
| Fundus Oculi | 5 | 2020 | 541 | 0.130 |
Why?
|
| Eye Diseases | 2 | 1992 | 651 | 0.130 |
Why?
|
| Middle Aged | 37 | 2024 | 220359 | 0.120 |
Why?
|
| Humans | 78 | 2024 | 760613 | 0.120 |
Why?
|
| Macular Degeneration | 2 | 2020 | 1002 | 0.120 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2016 | 708 | 0.120 |
Why?
|
| Retrospective Studies | 17 | 2023 | 80345 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 3725 | 0.110 |
Why?
|
| Phacoemulsification | 1 | 2014 | 149 | 0.100 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2014 | 190 | 0.100 |
Why?
|
| Optometry | 2 | 2008 | 29 | 0.100 |
Why?
|
| Retinal Vein Occlusion | 1 | 2014 | 149 | 0.100 |
Why?
|
| Male | 39 | 2024 | 359718 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 782 | 0.100 |
Why?
|
| Glaucoma | 2 | 2020 | 1182 | 0.100 |
Why?
|
| Diabetes Complications | 4 | 2010 | 1341 | 0.100 |
Why?
|
| Retinal Neoplasms | 1 | 2013 | 146 | 0.100 |
Why?
|
| Female | 39 | 2024 | 391246 | 0.100 |
Why?
|
| Laser Coagulation | 6 | 2014 | 329 | 0.090 |
Why?
|
| Adult | 27 | 2024 | 220007 | 0.090 |
Why?
|
| Cohort Studies | 7 | 2023 | 41337 | 0.090 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2011 | 94 | 0.090 |
Why?
|
| Aged, 80 and over | 15 | 2015 | 58980 | 0.090 |
Why?
|
| Aged | 29 | 2024 | 169143 | 0.090 |
Why?
|
| Refraction, Ocular | 1 | 2010 | 179 | 0.080 |
Why?
|
| Severity of Illness Index | 8 | 2021 | 15840 | 0.080 |
Why?
|
| Cataract | 3 | 2007 | 827 | 0.080 |
Why?
|
| Polypharmacy | 1 | 2010 | 307 | 0.070 |
Why?
|
| Light Coagulation | 3 | 1997 | 71 | 0.070 |
Why?
|
| Retinal Detachment | 3 | 2015 | 427 | 0.070 |
Why?
|
| Vitreous Hemorrhage | 2 | 2015 | 48 | 0.070 |
Why?
|
| Signal Processing, Computer-Assisted | 4 | 2012 | 1489 | 0.070 |
Why?
|
| Guideline Adherence | 3 | 2011 | 2283 | 0.070 |
Why?
|
| Cerebrovascular Circulation | 2 | 2007 | 2733 | 0.070 |
Why?
|
| Disease Progression | 7 | 2024 | 13505 | 0.070 |
Why?
|
| Consumer Health Information | 1 | 2008 | 209 | 0.060 |
Why?
|
| Audiovisual Aids | 1 | 2006 | 99 | 0.060 |
Why?
|
| Incidence | 1 | 2023 | 21391 | 0.060 |
Why?
|
| Prospective Studies | 9 | 2024 | 54306 | 0.060 |
Why?
|
| United States | 9 | 2023 | 72448 | 0.060 |
Why?
|
| Angiogenic Proteins | 1 | 2004 | 101 | 0.060 |
Why?
|
| Lipoproteins | 1 | 2007 | 882 | 0.050 |
Why?
|
| Retinol-Binding Proteins | 1 | 2022 | 67 | 0.050 |
Why?
|
| Program Development | 2 | 2011 | 1297 | 0.050 |
Why?
|
| Sensitivity and Specificity | 6 | 2016 | 14661 | 0.050 |
Why?
|
| Blood Flow Velocity | 1 | 2006 | 1377 | 0.050 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2002 | 45 | 0.050 |
Why?
|
| Medical Record Linkage | 1 | 2004 | 288 | 0.050 |
Why?
|
| Organizational Objectives | 1 | 2004 | 428 | 0.050 |
Why?
|
| Information Services | 1 | 2003 | 235 | 0.050 |
Why?
|
| Mass Screening | 2 | 2016 | 5422 | 0.050 |
Why?
|
| Tropicamide | 2 | 2013 | 22 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2002 | 326 | 0.050 |
Why?
|
| Models, Economic | 1 | 2005 | 719 | 0.050 |
Why?
|
| Quality Control | 1 | 2004 | 828 | 0.050 |
Why?
|
| Reproducibility of Results | 6 | 2012 | 20080 | 0.050 |
Why?
|
| Phenylephrine | 2 | 2013 | 293 | 0.040 |
Why?
|
| Eyelids | 1 | 2022 | 277 | 0.040 |
Why?
|
| Vision Disorders | 2 | 2005 | 1084 | 0.040 |
Why?
|
| Refractive Errors | 2 | 1992 | 145 | 0.040 |
Why?
|
| Young Adult | 7 | 2015 | 58748 | 0.040 |
Why?
|
| Health Policy | 1 | 2011 | 2677 | 0.040 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 3448 | 0.040 |
Why?
|
| Eye Proteins | 1 | 2022 | 633 | 0.040 |
Why?
|
| Patient Education as Topic | 2 | 2007 | 2315 | 0.040 |
Why?
|
| Optic Disk | 1 | 2002 | 421 | 0.040 |
Why?
|
| Vitreoretinopathy, Proliferative | 1 | 1998 | 68 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2022 | 3484 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2006 | 5201 | 0.040 |
Why?
|
| Disease Management | 1 | 2007 | 2514 | 0.030 |
Why?
|
| Referral and Consultation | 3 | 2005 | 3598 | 0.030 |
Why?
|
| Observer Variation | 3 | 2012 | 2601 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 5508 | 0.030 |
Why?
|
| Vision, Ocular | 1 | 1999 | 454 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2006 | 2688 | 0.030 |
Why?
|
| Pyrroles | 1 | 2002 | 1137 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2022 | 3802 | 0.030 |
Why?
|
| Corneal Diseases | 2 | 1992 | 536 | 0.030 |
Why?
|
| Drug Combinations | 2 | 2013 | 2025 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2002 | 1613 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 3 | 2016 | 2176 | 0.030 |
Why?
|
| Delivery of Health Care | 2 | 2010 | 5325 | 0.030 |
Why?
|
| Adolescent | 7 | 2015 | 87809 | 0.030 |
Why?
|
| Pseudophakia | 1 | 2014 | 60 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2006 | 8556 | 0.030 |
Why?
|
| Laser Therapy | 2 | 1994 | 1089 | 0.030 |
Why?
|
| Indoles | 1 | 2002 | 1829 | 0.030 |
Why?
|
| Time Factors | 4 | 2017 | 40139 | 0.030 |
Why?
|
| Computer Systems | 1 | 2015 | 470 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 2640 | 0.030 |
Why?
|
| Specialization | 2 | 2012 | 778 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 39262 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2013 | 193 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2005 | 3905 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2002 | 2049 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2006 | 6218 | 0.030 |
Why?
|
| Depth Perception | 1 | 2012 | 94 | 0.020 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2013 | 307 | 0.020 |
Why?
|
| Artifacts | 1 | 2020 | 1898 | 0.020 |
Why?
|
| Uveal Diseases | 1 | 1990 | 45 | 0.020 |
Why?
|
| Lebanon | 1 | 2011 | 245 | 0.020 |
Why?
|
| Risk Factors | 6 | 2015 | 74333 | 0.020 |
Why?
|
| Accommodation, Ocular | 1 | 1990 | 47 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 2 | 2005 | 7475 | 0.020 |
Why?
|
| Program Evaluation | 2 | 2011 | 2493 | 0.020 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2011 | 210 | 0.020 |
Why?
|
| Brain | 2 | 2007 | 26951 | 0.020 |
Why?
|
| Conjunctival Diseases | 1 | 1990 | 110 | 0.020 |
Why?
|
| Iris | 1 | 1990 | 231 | 0.020 |
Why?
|
| ROC Curve | 1 | 2017 | 3568 | 0.020 |
Why?
|
| Ophthalmoplegia | 1 | 1990 | 168 | 0.020 |
Why?
|
| Papilledema | 1 | 1990 | 130 | 0.020 |
Why?
|
| Italy | 1 | 2011 | 841 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 25941 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2013 | 838 | 0.020 |
Why?
|
| Orbital Diseases | 1 | 1990 | 178 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2005 | 4647 | 0.020 |
Why?
|
| Intraocular Pressure | 1 | 2014 | 1288 | 0.020 |
Why?
|
| Cytokines | 1 | 2022 | 7344 | 0.020 |
Why?
|
| Arginine | 1 | 2011 | 934 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 1994 | 1392 | 0.020 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2014 | 734 | 0.020 |
Why?
|
| Hyperventilation | 1 | 2007 | 79 | 0.020 |
Why?
|
| Lysine | 1 | 2011 | 1001 | 0.020 |
Why?
|
| Periaqueductal Gray | 1 | 2007 | 110 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 1204 | 0.020 |
Why?
|
| Hypoglycemic Agents | 2 | 2010 | 3149 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 1992 | 989 | 0.020 |
Why?
|
| Middle Cerebral Artery | 1 | 2006 | 276 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2006 | 281 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 3696 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2022 | 22052 | 0.010 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 2716 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 2011 | 988 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 1523 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 1490 | 0.010 |
Why?
|
| Age of Onset | 1 | 2010 | 3302 | 0.010 |
Why?
|
| Blindness | 2 | 1998 | 582 | 0.010 |
Why?
|
| Aspirin | 2 | 2004 | 3364 | 0.010 |
Why?
|
| Contrast Sensitivity | 1 | 2002 | 235 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2003 | 1628 | 0.010 |
Why?
|
| Health Facilities | 1 | 2005 | 578 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 2061 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2005 | 1257 | 0.010 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2005 | 919 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2020 | 26179 | 0.010 |
Why?
|
| Vitreous Detachment | 1 | 1999 | 22 | 0.010 |
Why?
|
| Blood Pressure | 2 | 2007 | 8525 | 0.010 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 666 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2005 | 1191 | 0.010 |
Why?
|
| Prevalence | 2 | 2011 | 15686 | 0.010 |
Why?
|
| Boston | 1 | 2010 | 9278 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1994 | 10343 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2006 | 6359 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2010 | 6379 | 0.010 |
Why?
|
| Visual Fields | 1 | 2002 | 1054 | 0.010 |
Why?
|
| Outpatients | 1 | 2003 | 1607 | 0.010 |
Why?
|
| Medicine | 1 | 2003 | 943 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 9468 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2007 | 36286 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1988 | 8055 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2002 | 2985 | 0.010 |
Why?
|
| Hypertension | 1 | 1992 | 8595 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2001 | 2001 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2004 | 3200 | 0.010 |
Why?
|
| Mutation | 1 | 2013 | 29957 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 12968 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1999 | 5961 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 1996 | 64981 | 0.000 |
Why?
|